Welcome to our dedicated page for Nuo Therapeutics SEC filings (Ticker: AURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuo Therapeutics, Inc. (OTCQB: AURX) SEC filings page provides direct access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a reporting company, Nuo Therapeutics submits documents such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and proxy statements on Schedule 14A.
For a commercial-stage medical device and biomedical company focused on chronic wound care, Annual Reports (Form 10-K) and Quarterly Reports (Form 10-Q) are central sources of information. These filings typically describe the Aurix System, summarize the company’s business and risk factors, and discuss reimbursement dynamics for autologous platelet-rich plasma (PRP) therapies used in chronic wound management. They also provide audited or reviewed financial statements and details on capital structure and liquidity.
Current Reports on Form 8-K capture significant events between periodic reports. For Nuo Therapeutics, 8-K filings have included information on recapitalization and exchange agreements that simplified the capital structure, responses to mini-tender offers, and corporate governance matters such as annual meeting results and executive compensation decisions. These filings help investors track material developments affecting the company’s operations and securities.
The company’s Definitive Proxy Statements (DEF 14A) offer insight into board composition, executive compensation programs, and matters submitted to stockholders at annual meetings, including the election of directors and ratification of the independent registered public accounting firm. They also describe how stockholders can participate in corporate governance, for example by submitting proposals or director nominations.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that highlight the key points of lengthy documents, such as complex 10-K risk factor sections or multi-item 8-Ks. Users can quickly see what each filing covers, then review the full text when deeper analysis is needed. Filings related to insider or executive matters, such as compensation decisions disclosed in 8-Ks or proxy statements, can be examined to understand how Nuo Therapeutics aligns management incentives with its chronic wound care business.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported receiving several derivative awards in the form of warrants linked to common stock at an exercise price of
Certain Second Warrants will vest, if at all, on
Nuo Therapeutics investor Scott M. Pittman reports beneficial ownership of 5,610,050 shares of common stock, or 11.6% of the company, based on 48,281,625 shares outstanding as of January 21, 2026. His holdings include 5,400,000 shares held directly, 30,050 shares issuable upon exercise of newly received warrants, and 180,000 shares underlying options.
The amendment also describes a secured loan arrangement where Pittman has loaned $200,000 to Nuo Therapeutics and committed to an additional $210,000 if requested. The notes bear interest at 10%, rising to 12% if a second closing occurs, and mature on December 31, 2028. Interest and certain prepayment fees are payable in stock warrants rather than cash, with multiple warrant series exercisable at $1.50 per share and expiring January 23, 2030, giving Pittman additional potential equity exposure through commitment, origination, capital coverage, prepayment, second-closing, and interest warrants.
Nuo Therapeutics, Inc. entered into a Loan and Security Agreement providing up to
As part of this financing, Nuo issued multiple series of common stock warrants at a
Nuo Therapeutics CEO/CFO and director David Jorden reported an insider stock option exercise. On 01/01/2026, he exercised an option to purchase 125,000 shares of Nuo Therapeutics, Inc. common stock at an exercise price of $0.40 per share using a net exercise method.
The company withheld 25,381 shares, valued at the closing price of $1.97 per share, to cover the exercise cost, and Jorden received 99,619 shares of common stock. Following these transactions, he directly beneficially owned 2,046,374 shares of Nuo Therapeutics common stock, and the reported option position was reduced to zero.
Nuo Therapeutics director reports option exercise and share withholding
A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025. The director exercised an option to purchase 68,750 shares of common stock at an exercise price of $0.4 per share, receiving 55,000 shares on a net basis. The issuer withheld 13,750 shares of common stock underlying the option to cover the exercise price, using the closing price of $2.00 per share. Following these transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 16, 2025. Stockholders elected four directors to the board, ratified the company’s independent auditor, and approved executive compensation on an advisory basis.
Director nominees David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer each received about 33.7 million votes in favor, with only a few thousand votes withheld and 2,237,142 broker non-votes. Stockholders ratified MaloneBailey LLP as independent registered public accounting firm with 35,917,807 votes for and 12,899 against, and approved the say-on-pay proposal with 33,653,458 votes for and 40,106 against, plus 2,237,142 broker non-votes.
Nuo Therapeutics, Inc. director reports stock option exercise. A director of Nuo Therapeutics exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share through a net exercise on December 9, 2025. The transaction resulted in the director receiving 40,909 shares of common stock, while 9,091 shares underlying the option were withheld to cover the exercise price using a closing market price of $2.20 per share. Following these transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.
Nuo Therapeutics, Inc. director filed a Form 4 reporting an option exercise and related share withholding. On 12/09/2025, the insider exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share. As part of a net exercise, the issuer withheld 9,091 shares of common stock at a closing price of $2.20 to cover the exercise cost, and the reporting person received 40,909 shares of common stock. Following these transactions, the insider directly beneficially owned 108,294 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden. On 11/28/2025, he reported a sale of 200,000 shares of common stock at $1.50 per share, leaving him with 1,946,755 shares beneficially owned directly after the trade. The filing notes that the transaction was executed as a private transaction in connection with a personal real estate transaction and that the shares involved are characterized as “restricted” securities under the Securities Act of 1933.
Nuo Therapeutics (AURX) reported Q3 2025 results showing faster top-line growth but ongoing losses and liquidity pressure. Total revenue rose to $1,032,096 from $370,951 a year ago, driven by $957,096 in product sales and $75,000 recognized from the Smith+Nephew distribution fee. Gross profit was $625,375; gross margin was 61% versus 73% last year due to low‑margin centrifuge device sales to Smith+Nephew and tariff surcharges, partly offset by fee revenue with no cost.
Operating expenses were $1,165,517, and net loss was $537,919 (basic/diluted loss per share $0.01). For the nine months, revenue reached $2,216,679 with a net loss of $1,933,736. Cash was $514,797 as of September 30, 2025, with total deferred revenue of $1,350,000 tied to the Smith+Nephew upfront distribution fee. The company raised $791,418 in a July private placement and $113,541 from option exercises. Management states substantial doubt about the ability to continue as a going concern, citing expected cash needs beyond current resources despite the new distribution agreement.
FAQ
What is the current stock price of Nuo Therapeutics (AURX)?
What is the market cap of Nuo Therapeutics (AURX)?
